Reveille JD, Deodhar A, Caldron PH, et al. - A total of 208 patients were randomly assigned to IV infusions of golimumab (GOL) 2 mg/kg (n = 105) at weeks 0, 4, and every 8 weeks following or placebo (n = 103) at weeks 0, 4, and 12, then crossover to GOL at weeks 16, 20, and every 8 weeks thereafter through Week 52 in order to assess safety and efficiency of IV GOL in individuals with active ankylosing spondylitis (AS, an immune-mediated disease identified by inflammatory back pain and progressive spinal stiffness) through 1 year. Efficiency was concluded to be sustained through 1 year with IV GOL 2 mg/kg among individuals with active AS. Moreover, adverse events were uniform with the known safety characterization of GOL.